Evidence map›Paper›PMID 30307486›Full record

ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2019

Direct Diagnostic Tests for Lyme Disease.

Steven E Schutzer, Barbara A Body, Jeff Boyle, Bernard M Branson, Raymond J Dattwyler, Erol Fikrig, Noel J Gerald, Maria Gomes-Solecki, Martin Kintrup, Michel Ledizet and 17 more

Abstract readReview
In one paragraph

Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Presence of Borrelia Spirochetes in White Stork (Animals : an open access journal from MDPI · 2024
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Genomic hybrid capture assay to detectJournal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc · 2022
    Article
  12. Persistent Symptoms After Treatment of Lyme Disease.Infectious disease clinics of North America · 2022
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Observational
  18. Review
  19. Article
  20. Detection of Borrelia burgdorferi Cell-free DNA in Human Plasma Samples for Improved Diagnosis of Early Lyme Borreliosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Steven E SchutzerDepartment of Medicine, Rutgers New Jersey Medical School, Newark.
Barbara A BodyLaboratory Corporation of America, Burlington, North Carolina.
Jeff BoyleQiagen, Inc., Germantown, Maryland.
Bernard M BransonScientific Affairs, LLC, Atlanta, Georgia.
Raymond J DattwylerDepartment of Microbiology/Immunology, New York Medical College, Valhalla.
Erol FikrigDepartment of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.
Noel J GeraldOffice of In Vitro Diagnostics and Radiological Health, Food and Drug Administration, Department of Health and Human Services, Silver Spring, Maryland.
Maria Gomes-SoleckiDepartment of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis.
Martin KintrupViramed Biotech AG, Planegg, Germany.
Michel LedizetL2 Diagnostics, LLC, New Haven, Connecticut.
Andrew E LevinKephera Diagnostics, Wellesley, Massachusetts.
Michael LewinskiRoche Diagnostics, Pleasanton, California.
Lance A LiottaCenter for Applied Proteomics and Molecular Medicine, College of Science, George Mason University, Manassas, Virginia.
Adriana MarquesClinical Studies Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Paul S MeadDivision of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado.
Emmanuel F MongodinDepartment of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore.
Segaran PillaiOffice of Laboratory Science and Safety, US Food and Drug Administration, Department of Health and Human Services, Silver Spring, Maryland.
Prasad RaoOffice of In Vitro Diagnostics and Radiological Health, Food and Drug Administration, Department of Health and Human Services, Silver Spring, Maryland.
William H RobinsonDepartment of Medicine, Stanford University School of Medicine, California.
Kristian M RothOffice of In Vitro Diagnostics and Radiological Health, Food and Drug Administration, Department of Health and Human Services, Silver Spring, Maryland.
Martin E SchrieferDivision of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado.
Thomas SlezakLawrence Livermore National Laboratory, California.
Jessica L SnyderT2 Biosystems, Inc., Lexington, Massachusetts.
Allen C SteereDepartment of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston.
Jan WitkowskiCold Spring Harbor Laboratory, New York.
Susan J WongWadsworth Center, New York State Department of Health, Albany.
John A BrandaDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston.

Funding

Assessment Of Patients With Borrelia InfectionZIAAI000695 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MARQUES, ADRIANA R · 2009 to 2025
$8.8M
Borrelia burgdorferi-Induced Autoimmunity in Lyme DiseaseR01AI101175 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI STEERE, ALLEN C · 2013 to 2021
$3.6M
A serologic assay to measure successful Lyme borreliosis antibiotic therapyR44AI085725 · NIAID · L2 DIAGNOSTICS, LLC · PI LEDIZET, MICHEL · 2014 to 2016
$2.6M
Diagnostic Assays for early Lyme Borreliosis using in-vivo expressed antigensR44AI096598 · NIAID · L2 DIAGNOSTICS, LLC · PI LEDIZET, MICHEL · 2014 to 2015
$1.7M
Point of care assay for serodiagnosis of LeptospirosisR43AI136551 · NIAID · IMMUNO TECHNOLOGIES, INC. · PI GOMES-SOLECKI, MARIA · 2018 to 2019
$600k
NIAID NIH HHS R01 AI101175NIAID NIH HHS R43 AI136551NIAID NIH HHS R44 AI085725NIAID NIH HHS R44 AI096598
6 · The paper itself

Abstract

Borrelia burgdorferi was discovered to be the cause of Lyme disease in 1983, leading to seroassays. The 1994 serodiagnostic testing guidelines predated a full understanding of key B. burgdorferi antigens and have a number of shortcomings. These serologic tests cannot distinguish active infection, past infection, or reinfection. Reliable direct-detection methods for active B. burgdorferi infection have been lacking in the past but are needed and appear achievable. New approaches have effectively been applied to other emerging infections and show promise in direct detection of B. burgdorferi infections.

Indexed as

Borrelia burgdorferiDiagnostic Tests, RoutineGenomicsHigh-Throughput Screening AssaysHumansLyme DiseasePolymerase Chain ReactionSerologic TestsBorrelia burgdorferihigh-throughput sequencingLyme diseasePCRtests

Identifiers

PMID30307486
PMCPMC6399434

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.